Valneva (VALN) announced that the Brazilian Health Regulatory Agency has granted marketing authorization to its single-dose vaccine Ixchiq for the prevention of disease caused by the chikungunya virus in individuals 18 years of age and older. The decision marks the world’s first approval of a chikungunya vaccine in an endemic country, the company said in a statement. ANVISA continues to review VLA1555, the chikungunya vaccine candidate which, if approved, will be locally manufactured and distributed by Instituto Butantan pursuant to its collaboration with Valneva. Potential approval is anticipated in mid-2025.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VALN:
- Positive Outlook for Valneva Driven by Promising Vaccine Pipeline and Strategic Developments
- Valneva and LimmaTech Initiate Phase 2 Study of Shigella Vaccine
- Valneva’s Chikungunya Vaccine Gains EU Approval for Adolescents
- Valneva granted EC marketing authorization for Ixchiq vaccine
- Valneva’s Strategic Advancements and Promising Projections Drive Buy Rating with $17 Target
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue